<DOC>
	<DOCNO>NCT01453946</DOCNO>
	<brief_summary>A Safety Maintenance Entocort EC child mild moderate Crohn 's Disease .</brief_summary>
	<brief_title>Safety Maintenance Study Entocort Children With Crohn 's Disease</brief_title>
	<detailed_description>A Multicenter , Open label , Non-comparative Study Evaluate Safety Entocort EC Maintenance Treatment Crohn 's Disease Paediatric Subjects Aged 5 17 Years , Inclusive</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>All male female subject must age 5 17 , inclusive , must reach 18th birthday estimate final office visit . All subject must weight &gt; = 15 kg time enrollment . Subjects must diagnose treat active Crohn 's disease ileum and/or ascend colon confirm endoscopic and/or radiographic evidence , and/or evidence mucosal erosion and/or histology PCDAI &lt; = 10 Subjects previous intestinal resection proximal include ascend colon . Subjects evidence active Crohn 's disease ( PCDAI &gt; 10 ) and/or stricturing , prestenotic dilatation , clinical evidence obstruction , perirectal abscess , perirectal disease active draining fistula , perforation , septic complication . Subjects morning cortisol level &lt; 150 nmol/l ( 5.4 ug/dl ) DHEAS normal range age gender ( NOTE : Subjects induction protocol abnormal morning cortisol/DHEAS level Visit 4 , otherwise meet eligibility criterion , may enrol investigator decides Entocort 6 mg appropriate therapy option .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>